经动脉灌注化学治疗中晚期胃癌的临床效果

目的探讨经动脉灌注化学治疗(简称化疗)中晚期胃癌的临床效果。方法将80例中晚期胃癌患者随机分为观察组和对照组,每组40例。观察组给予DSA引导下经动脉灌注化疗,对照组采用常规SOX方案化疗,比较2组化疗3、6个周期后的疗效,并统计不良反应。绘制2组患者随访24个月时无进展生存时间曲线,比较无进展生存时间。结果3个周期化疗结束时,观察组治疗有效率69.44%(25/36),高于对照组的38.46%(15/39)(P=0.028);6个周期结束时,观察组治疗有效率58.82%(20/34),对照组为41.67%(15/36),组间差异无统计学意义(P=0.511)。6个周期化疗期间2组患者不良反应差异无统计学意义(P均>0.05)。随访24个月时,观察组、对照组中位无进展生存期分别为6.5、6.0个月,组间比较差异有统计学意义(P=0.041)。结论动脉置管持续灌注化疗对中晚期胃癌的短期疗效优于常规SOX化疗方案,并可延长患者无进展生存期,且较安全。

Efficacy of transcatheter arterial infusion chemotherapy for advanced gastric cancer

Objective To explore the curative effect of transcatheter arterial infusion chemotherapy in treatment of advanced gastric cancer (AGC). Methods Totally 80 AGC patients were randomly divided into observation group and control group (each n=40). Patients in observation group were treated with transcatheter arterial infusion chemotherapy, and those in control group were given SOX regimen. The therapeutic efficacy were compared between groups at the end of 3rd and 6th cycle of chemotherapy, and the adverse reactions were counted. Follow up was performed for 24 months, and progression-free survival time curve was drawn and compared between 2 groups. Results At the end of 3rd cycle, the effective rate was 69.44% (25/36) of observation group, higher than that of control group (38.46%15/39], P=0.028). At the end of 6th cycle, the effective rate was 58.82% (20/34) of observation group, 41.67% (15/36) in control group (P=0.511). During 6 cycles of chemotherapy, no significant difference of incidence of side effect was found between 2 groups (P>0.05). After 24 months follow-up, the median progression-free survival was 6.5 months in observation group, 6.0 months in control group (P=0.041). Conclusion Transcatheter arterial infusion chemotherapy has better short-term curative effect than SOX regimen for treating advanced gastric cancer, which may prolong progression-free survival of patients and be relatively safe.